Vaccine research has increasingly focused on virus-like particles (VLPs) due to their unique ability to mimic the structures of viruses without containing ...
In the Virus-Like Particle Translational Oncology Laboratory, Qizhi Cathy Yao, M.D., Ph.D. is developing non-infectious HIV virus-like particles (VLPs) as candidate HIV mucosal vaccines for both ...
The formation of VLP is depicted in Figure 1. Figure 1. The formation of a virus-like particle (VLP). Image Credit: Sino Biological Inc. To enable targeted drug research, Sino Biological has ...
Hosted on MSN27d
Bavarian Nordic gets FDA approval for chikungunya vaccineThe virus-like particle, or VLP, vaccine is approved for people aged 12 and older. The company plans to launch the product in the U.S. in the first half of the year, according to a statement.
Pharmaceutical Technology on MSN10d
EC approves Bavarian Nordic’s chikungunya vaccine marketingThe European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback